Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: A dose-finding study in patients with advanced breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 6, 1996, Pages 487-494

  Venturini, Marco ^a   Del Mastro, Lucia ^a   Testore, Franco ^b   Danova, Marco ^c   Garrone, Ornella ^a   Lanfranco, Claudio ^b   Latini, Fabio ^d   Sertoli, Mario R ^e   Lionetto, Rita ^a   Queirolo, Paola ^a   Ardizzoni, Andrea ^a   Rosso, Riccardo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Ospedale Civile   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d Direzione Medica   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

Author keywords

Breast cancer; CEF; Dose intensity; Erythropoietin; GM CSF

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ERYTHROPOIETIN; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PARACETAMOL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE PAIN; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTITIS; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MENOPAUSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OUTPATIENT; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VOMITING;

EID: 9544236210     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050516     Document Type: Article

References (23)

1. Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288
2. Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Laroque G, Mayers C, Perrault D, Sutherland H (1988) A randomized trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377-1387
3. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR, Colangelo Ballow A, Frei E III, Henderson C (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:253-259
4. Venturini M, Del Mastro L, Ardizzoni A, Sertoli MR, Mariani GL, Pennucci MC, Garrone O, Silvestro S, Addamo GF, Queirolo P, Rosso R (1993) High dose intensity chemotherapy without bone marrow support: role of granulocyte-macrophage colony-stimulating factor. Ann NY Acad Sci 698:389-397
5. Gerhartz HH, Engelhard M, Meusers P, Brittinger G, Wilmanns W, Schlimok G, Mueller P, Huhn D, Musch R, Siegert W, Gerhartz D, Hartlapp J, Thiel E, Huber C, Peschl C, Spann W, Emmerich B, Schadek C, Westerhausen M, Pees HW, Radtke H, Engert A, Terhardt E, Schick H, Binder T, Fuchs R, Hasford J, Brandmaier R, Stern AC, Tiemann M, Lennert K (1993) Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 82:2329-2339
6. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Dabbara I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishar W, Yahanda A, Vicent M, Stewart M, Glaspy J (1988) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 325:164-170
7. Ardizzoni A, Venturini M, Sertoli MR, Giannessi PG, Brema F, Danova M, Testore F, Mariani GL, Pennucci MC, Queirolo P, Silvestro S, Bruzzi P, Lionetto R, Latini F, Rosso R (1994) Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose-intensity increase of CEF chemotherapy. A randomised study in patients with advanced stage breast cancer. Br J Cancer 69:385-391
8. Del Mastro L, Garrone O, Sertoli MR, Canavese G, Catturich A, Guenzi M, Rosso R, Venturini M (1994) A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte-colony stimulating factor as adjuvant therapy in early breast cancer. Eur J CAncer 30A:606-610
9. Case DC Jr, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols CR, Salmon SE, Silver RT, Storniolo AM, Wampler GL, Dooley CM, Larholt KM, Nelson RA, Abels RI (1993) Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85:801-806
10. Kurzrock R, Talpaz M, Gutterman JU (1992) Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anaemia. Am J Med 93:41-48
11. Pedrazzini A (1993) Erythropoietin and GM-CSF following autologous bone marrow transplantation. Eur J Cancer 29A [Suppl 2] :S15-S17
12. Krumwieh D, Siebold B, Weinmann E, Weinmann E, Seiler FR (1991) Combined effect of granulocyte-macrophage colony stimulating factor with erythropoietin in subhuman primates. Am J Clin Oncol 14 [Suppl 1] :S1-S4
13. American Joint Committee on Cancer (1992) Breast manual for staging of cancer, 4th edn. Lippincott, Philadelphia, pp 149-154
14. Miller AB, Hoogstraten AB, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
15. Lieschke GJ, Cebon J, Morstyn G (1989) Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony stimulating factor. Blood 74:2634-2643
16. Ardizzoni A, Venturini M, Crinò L, Sertoli MR, Bruzzi P, Pennucci MC, Mariani GL, Garrone O, Bracarda S, Rosso R, Van Zandwijk N (1993) High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer. Eur J Cancer 29A:687-692
17. Henderson IC, Harris JR, Kinne DW, Hellman S (1989) Cancer of the breast. In: De Vita VT Jr. Hellman S, Rosemberg SA (eds) Cancer: principles and practice of oncology, 3rd edn. Lippincott, Philadeplphia, pp 1197-1268
18. O'Shaughnessy JA, Denicoff AM, Venzon DJ, Danforth D, Pierce LJ, Frame JN, Bastian A, Ghosh B, Goldspiel B, Miller L, Dorr FA, Keegan P, Ben-Baruch N, Mrose H, Noone M, Cowan KH (1994) A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients. Ann Oncol 5:709-716
19. Mamounas EP, Anderson S, Wickerham DL, Clark R, Stoller R, Hamm JT, Stewart JA, Bear HD, Glass AG, Bornstein R, Fisher B (1994) The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. Am J Clin Oncol 17:374-381
20. Hoekman K, Wagstaff J, Van Groeningen CJ, Vermorken JB, Boven E, Pinedo HM (1991) Effects of recombinant human granulocyte-macrophage colony stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer. J Natl Cancer Inst 83:1546-1553
21. Bonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, Casali P, Demicheli R, Valagussa P (1993) Drugs ten years later: epirubicin. Ann Oncol 4:351-369
22. Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L, Dexter TM (1989) The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60:121-125
23. Hamm J, Schiller JH, Cuffie C, Oken M, Fisher RI, Shepherd F, Kaiser G (1994) Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small cell lung carcinoma. J Clin Oncol 12:2667-2676